These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34709729)

  • 21. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
    Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
    J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
    [No Abstract]   [Full Text] [Related]  

  • 22. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
    McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
    J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
    Nichols D; Gifford A; Russell R; Odem-Davis K; Young J; Amaro-Galvez R; Billings J; Mukadam Z; Mayer-Hamblett N
    Ann Am Thorac Soc; 2024 Feb; 21(2):360-362. PubMed ID: 38019099
    [No Abstract]   [Full Text] [Related]  

  • 26. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 27. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
    Nathan N; Thouvenin G; Dubern B; Corvol H
    Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
    [No Abstract]   [Full Text] [Related]  

  • 28. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 30. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
    Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 33. Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy!
    Martin C; Regard L; Chassagnon G; Burgel PR
    Am J Respir Crit Care Med; 2022 Jun; 205(11):1365-1366. PubMed ID: 35358030
    [No Abstract]   [Full Text] [Related]  

  • 34. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
    Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis.
    Wisniewski BL; Aylward SC; Jordan CO; Kopp BT; Paul GR
    J Cyst Fibros; 2022 May; 21(3):e217-e220. PubMed ID: 35131172
    [No Abstract]   [Full Text] [Related]  

  • 39. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
    FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
    Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.